DrugPatentWatch Database Preview
Drugs in Development Information for Clazakizumab
» See Plans and Pricing
What is the drug development status for Clazakizumab?
Clazakizumab is an investigational drug.
There have been 9 clinical trials for Clazakizumab.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2019.
The most common disease conditions in clinical trials are Infection, Coronavirus Infections, and Asthma. The leading clinical trial sponsors are Vitaeris INC, Medical University of Vienna, and NYU Langone Health.
There are four US patents protecting this investigational drug and twenty-five international patents.
Summary for Clazakizumab
| US Patents | 4 |
| International Patents | 25 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2019-03-01) |
| Vendors | 0 |
Recent Clinical Trials for Clazakizumab
| Title | Sponsor | Phase |
|---|---|---|
| Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection | NYU Langone Health | Phase 2 |
| Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection | Vitaeris INC | Phase 2 |
| Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection | Columbia University | Phase 2 |
Clinical Trial Summary for Clazakizumab
Top disease conditions for Clazakizumab
Top clinical trial sponsors for Clazakizumab
US Patents for Clazakizumab
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Clazakizumab | Start Trial | Soluble C5aR antagonists | ChemoCentryx, Inc. (Mountain View, CA) | Start Trial |
| Clazakizumab | Start Trial | Cholestosome vesicles for incorporation of molecules into chylomicrons | THERASYN SENSORS, INC. (Eggertsville, NY) | Start Trial |
| Clazakizumab | Start Trial | Soluble C5aR antagonists | ChemoCentryx, Inc. (Mountain View, CA) | Start Trial |
| Clazakizumab | Start Trial | Binding-triggered transcriptional switches and methods of use thereof | The Regents of the University of California (Oakland, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Clazakizumab
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Clazakizumab | Argentina | 108097 | 2036-04-04 | Start Trial |
| Clazakizumab | Australia | 2017246228 | 2036-04-04 | Start Trial |
| Clazakizumab | Brazil | 112018070214 | 2036-04-04 | Start Trial |
| Clazakizumab | Canada | 3019137 | 2036-04-04 | Start Trial |
| Clazakizumab | Chile | 2018002803 | 2036-04-04 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
